According to a report by Intel Market Research, the global Cardiac Marker Rapid Test Market was valued at USD 732 million in 2025 and is estimated to reach USD 785 million in 2026, before growing to USD 1.38 billion by 2034, representing a 7.3% CAGR during 2026–2034. Cardiac marker rapid tests detect biomarkers such as troponin, CK-MB and myoglobin to support diagnosis, triage and monitoring across acute and selected chronic cardiovascular pathways. (Intel Market Research)
The source page also contains an earlier presentation showing USD 682 million in 2024, USD 732 million in 2025 and USD 1.10 billion by 2031. The page therefore contains two forecast frameworks; this PR uses the current 2025–2034 framework and flags the earlier figures rather than reconciling them. (Intel Market Research)
Explore the full report: Cardiac Marker Rapid Test Market report
Why Is Demand Increasing?
- Cardiovascular disease burden: WHO estimates 19.8 million cardiovascular deaths in 2022, representing roughly 32% of global deaths, supporting demand for rapid diagnostic pathways. (Intel Market Research)
- High-sensitivity troponin: Newer assays can identify lower concentrations earlier and support accelerated serial-testing strategies.
- Point-of-care expansion: Whole-blood and compact-analyzer formats can reduce sample transport and laboratory delays in emergency and near-patient environments. (Intel Market Research)
Diagnostics Technology & Emergency-Care Watch
Cardiac rapid testing is increasingly moving toward laboratory-grade sensitivity closer to the patient. The report highlights high-sensitivity troponin as the central technology trend, with whole-blood testing, fingerstick sampling, compact readers and connectivity becoming important workflow differentiators. Recent regulatory activity has broadened the competitive field, including Abbott’s i-STAT hs-TnI clearances, QuidelOrtho’s VITROS hs Troponin I clearance and Roche’s high-sensitivity Troponin T developments. At the same time, rapid testing remains clinically demanding because results must be interpreted alongside symptoms, ECG findings and timing. This makes quality management, calibration, connectivity and standardized clinical algorithms important elements of commercial differentiation. (Intel Market Research)
Segmentation Highlights
- By Type: Troponin, CK-MB, Myoglobin and Others.
- Leading Marker: Troponin remains the leading biomarker because high-sensitivity cardiac troponin is embedded in acute myocardial-infarction pathways. (Intel Market Research)
- By Application: Myocardial Infarction, Heart Failure and Others.
- Myocardial infarction remains the core application, while heart-failure and broader acute-care panels add incremental demand.
- By Format: Rapid and near-patient tests, including cartridge, strip and compact-analyzer formats. (Intel Market Research)
Regional Outlook
- North America remained the largest regional market in 2025, supported by emergency-care testing intensity, IVD adoption and regulatory activity. (Intel Market Research)
- Asia-Pacific offers the strongest volume-growth opportunity as acute-care infrastructure expands.
- The United States combines significant acute cardiovascular event volumes with an active high-sensitivity troponin regulatory environment.
- Europe and other developed markets continue to adopt accelerated cardiac-testing pathways and near-patient technologies. (Intel Market Research)
Download the free sample report: Access the free sample from the IMR report page
Why This Market Matters
The Cardiac Marker Rapid Test Industry is becoming an important component of faster acute-care decision-making. Rapid biomarker testing can help reduce delays between blood collection and actionable results, particularly where emergency departments need accelerated chest-pain triage. (Intel Market Research)
The commercial opportunity increasingly centers on combining sensitivity with workflow simplicity. Suppliers must demonstrate reliable performance while addressing whole-blood capability, connectivity, quality control, regulatory requirements and clinical interpretation. These requirements favor companies with established analyzer ecosystems and strong validation capabilities. (Intel Market Research)
Competitive Landscape
- Roche Diagnostics — Competes through high-sensitivity cardiac assays and established diagnostic infrastructure.
- Siemens Healthineers — Differentiates through rapid testing platforms, analyzer integration and point-of-care capabilities.
- Abbott Laboratories — Competes through i-STAT cardiac testing and broader diagnostic platforms.
- Beckman Coulter — Benefits from established hospital relationships, assay menus and service networks.
- Randox Laboratories — Participates in the cardiac biomarker and rapid-diagnostic competitive landscape. (Intel Market Research)
View the full report: Full Cardiac Marker Rapid Test Market Report
FAQ
Q: What is the Cardiac Marker Rapid Test Market size and forecast?
A: The current IMR framework values the market at USD 732 million in 2025, USD 785 million in 2026 and USD 1.38 billion by 2034 at a 7.3% CAGR. (Intel Market Research)
Q: Which region leads the market?
A: North America remained the largest regional market in 2025. (Intel Market Research)
Q: Which biomarker leads the market?
A: Troponin remains the leading biomarker segment, driven by its role in acute myocardial-infarction diagnostic pathways. (Intel Market Research)
What Does the Full Report Cover?
The full report provides detailed Market Size, Share, Growth and Forecast analysis through 2034, covering troponin, CK-MB, myoglobin and other cardiac markers. It examines myocardial infarction, heart failure and other applications across North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. The study also evaluates high-sensitivity assays, whole-blood testing, point-of-care workflows, digital connectivity, analyzer ecosystems, regulatory clearances and quality-management requirements. Competitive profiles assess major diagnostics companies and specialized point-of-care suppliers, while the report considers assay sensitivity, turnaround time, sample handling, installed-base advantages, clinical interpretation and commercialization requirements. (Intel Market Research)
View the complete report: Complete Cardiac Marker Rapid Test Market Report
Download the free sample: IMR Cardiac Marker Report Page
Related Reports
No related IMR report URLs were supplied or verified from the source page.
About Intel Market Research
Intel Market Research provides strategic intelligence, forecasts, competitive analysis and market research across healthcare, diagnostics, medical devices and related industries.
Contact Details
Website: www.intelmarketresearch.com | Asia-Pacific: +91 9169164321
